Fig. 3From: Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)Median overall survival (OS; large dots) and interquartile range (smaller dots and shaded bars) by year of trastuzumab for MBC initiation. The dotted lines indicate the trend in median OS over time. NR = median not reachedBack to article page